Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Wasserman

Showing results (201-210 of 299) with videos related to

Pageof 30
Sort By:
Lancet (London, England)|October 6, 2014
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trialFrederick J Raal, Narimon Honarpour, Dirk J Blom, et al.
Neurobiology of Disease|June 11, 2025
Early and widespread cerebellar engagement during hippocampal seizures and interictal dischargesM L Streng, B W Kottke, E M Wasserman, et al.
Biorxiv : the Preprint Server for Biology|May 27, 2024
Early and widespread cerebellar engagement during hippocampal seizures and interictal dischargesM L Streng, B W Kottke, E M Wasserman, et al.
Journal of Traumatic Stress|April 2, 2020
Parental Wartime Deployment and Socioemotional Adjustment in Early Childhood: The Critical Role of Military Parents' Perceived Threat During DeploymentNastassia J Hajal, Hilary J Aralis, Cara J Kiff, et al.
Circulation|December 13, 2016
Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein MetabolismGerald F Watts, Dick C Chan, Ricardo Dent, et al.
Diabetes Research and Clinical Practice|May 24, 2024
Text messaging to enhance glucose monitoring and self-care in teens with type 1 diabetes: Teens' perceptions predict outcomesCharlotte W Chen, Emily Serata, Rachel Scheub, et al.
Cardiovascular Drugs and Therapy|March 4, 2016
Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 StudyLeslie Cho, Michael Rocco, David Colquhoun, et al.
Clinical Cardiology|August 19, 2018
Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studiesErik Stroes, Jennifer G Robinson, Frederick J Raal, et al.
Clinical Cardiology|January 31, 2014
Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapyLeslie Cho, Michael Rocco, David Colquhoun, et al.
Medical Hypotheses|November 1, 1995
Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitusY Klipper-Aurbach, M Wasserman, N Braunspiegel-Weintrob, et al.
Pageof 30

Showing results (201-210 of 299) with videos related to

Sort By:
Pageof 30
Lancet (London, England)|October 6, 2014
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trialFrederick J Raal, Narimon Honarpour, Dirk J Blom, et al.
Neurobiology of Disease|June 11, 2025
Early and widespread cerebellar engagement during hippocampal seizures and interictal dischargesM L Streng, B W Kottke, E M Wasserman, et al.
Biorxiv : the Preprint Server for Biology|May 27, 2024
Early and widespread cerebellar engagement during hippocampal seizures and interictal dischargesM L Streng, B W Kottke, E M Wasserman, et al.
Journal of Traumatic Stress|April 2, 2020
Parental Wartime Deployment and Socioemotional Adjustment in Early Childhood: The Critical Role of Military Parents' Perceived Threat During DeploymentNastassia J Hajal, Hilary J Aralis, Cara J Kiff, et al.
Circulation|December 13, 2016
Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein MetabolismGerald F Watts, Dick C Chan, Ricardo Dent, et al.
Diabetes Research and Clinical Practice|May 24, 2024
Text messaging to enhance glucose monitoring and self-care in teens with type 1 diabetes: Teens' perceptions predict outcomesCharlotte W Chen, Emily Serata, Rachel Scheub, et al.
Cardiovascular Drugs and Therapy|March 4, 2016
Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 StudyLeslie Cho, Michael Rocco, David Colquhoun, et al.
Clinical Cardiology|August 19, 2018
Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studiesErik Stroes, Jennifer G Robinson, Frederick J Raal, et al.
Clinical Cardiology|January 31, 2014
Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapyLeslie Cho, Michael Rocco, David Colquhoun, et al.
Medical Hypotheses|November 1, 1995
Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitusY Klipper-Aurbach, M Wasserman, N Braunspiegel-Weintrob, et al.
Pageof 30